Variation in Use of Androgen Suppression With External-Beam Radiotherapy for Nonmetastatic Prostate Cancer

This publication has 18 references indexed in Scilit:

• Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer
  New England Journal of Medicine, 2010
• Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
  International Journal of Radiation Oncology*Biology*Physics, 2009
• Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
  Journal of Clinical Oncology, 2009
• Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population
  Cancer, 2008
• Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs
  Journal of General Internal Medicine, 2007
• Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
  Journal of Clinical Oncology, 2006
• Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma
  Cancer, 2005
• Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31
  International Journal of Radiation Oncology*Biology*Physics, 2005
• Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma
  Cancer, 2005
• Overview of the SEER-Medicare Data
  Medical Care, 2002